Business · 18/07/1997Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for ARICEPT Patent Extension
Summary
The Food and Drug Administration has officially confirmed the regulatory review period for the patent extension of ARICEPT, a human drug product, following a submission to the Department of Commerce for patent extension.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →